Researcher profile

Matt Kaeberlein, PhD

He co-authored the 2005 work identifying the fluorophore artifact that undermined the original sirtuin–resveratrol result, and he co-directs the only randomized lifespan trial running in a large mammal outside a laboratory colony.

Role
Biogerontologist; co-founder of the Dog Aging Project; CEO of Optispan
Affiliation
formerly Professor of Pathology, University of Washington
Topics
Rapamycin · Dogs & TRIAD · Resveratrol · Supplement scepticism

Why we quote Kaeberlein

He co-authored the 2005 work identifying the fluorophore artifact that undermined the original sirtuin–resveratrol result, and he co-directs the only randomized lifespan trial running in a large mammal outside a laboratory colony.

Matt Kaeberlein, PhD is one of the researchers quoted here; the others quoted alongside Matt are listed with the same disclosures.

Where they stand, and who pays

Runs a commercial healthspan company, and is the most consistently sceptical voice quoted on this site about the supplement industry, including categories he could profit from.

Stating this next to the quote rather than at the bottom of a disclosures page is the whole point. A concession made against a commercial interest is stronger evidence than a neutral summary; a claim made in line with one is weaker. You cannot weigh either without knowing which you are reading.

Every line below is transcribed from a public recording and linked back to it. Nothing here is paraphrased, and Kaeberlein has no relationship with this site.

Everything we quote them saying

All 9 lines, verbatim, in the order they appear in the site's citation index. Each one links to the recording and to the page it is used on.

A study that would take 30 years in people will take three and a half years in dogs.

Matt Kaeberlein, PhD(profile) Co-director of the Dog Aging Project and former Professor of Pathology, University of Washington Longevity Science lecture, 2026

Used on Rapamycin for dogs: what the 24-dog trial actually showed

About 15% of people taking rapamycin 6 mg once a week will develop mouth sores.

Matt Kaeberlein, PhD(profile) CEO, Optispan, on a survey of 333 off-label users Is Rapamycin Dead?, 2026

Used on Rapamycin Side Effects: What the Dose Actually Changes , Rapamycin: What the Evidence Shows

Dogs age very much like we do, they just do it seven to 10 times faster.

Matt Kaeberlein, PhD(profile) Co-director of the Dog Aging Project and former Professor of Pathology, University of Washington Longevity Science lecture, 2026

Used on Rapamycin and the Dog Aging Project: What TRIAD Is Testing

Nobody's going to make enough money off of rapamycin to do the clinical trials that really should be done.

Matt Kaeberlein, PhD(profile) CEO, Optispan, and Professor of Pathology, University of Washington Is Rapamycin Dead?, 2026

Used on Rapamycin vs Metformin: What the New Meta-Analysis Changed

One dog got high triglycerides. That's it.

Matt Kaeberlein, PhD(profile) Co-director of the Dog Aging Project, on side effects across two rapamycin safety trials in dogs Longevity Science lecture, 2026

Used on Rapamycin for dogs: what the 24-dog trial actually showed

Only 12 weeks of rapamycin was enough to increase remaining life expectancy by more than 60%.

Matt Kaeberlein, PhD(profile) Professor of Pathology, University of Washington, on a short-course mouse experiment Is Rapamycin Dead?, 2026

Used on How Rapamycin Works on mTOR, in Plain Language , Rapamycin Dosage for Longevity: What the Numbers Rest On

Take the fluorophore off, and resveratrol does absolutely nothing to this chemical reaction.

Matt Kaeberlein, PhD(profile) co-author of the 2005 study that identified the sirtuin assay artifact Optispan, 2024

Used on Resveratrol Supplement: What Happened to the Longevity Claim

The net effect of resveratrol is a 0% effect on lifespan.

Matt Kaeberlein, PhD(profile) biogerontologist, University of Washington, CEO of Optispan Optispan, 2024

Used on Resveratrol Benefits, Sorted by What Was Measured in Humans , Resveratrol Supplement: What Happened to the Longevity Claim

There's nothing saying that 6 mg is the best dose.

Matt Kaeberlein, PhD(profile) Professor of Pathology, University of Washington Is Rapamycin Dead?, 2026

Used on Rapamycin Dosage for Longevity: What the Numbers Rest On

The standing disclaimer

Matt Kaeberlein, PhD has no relationship with Rapamycin.store and does not endorse anything on it.

  • They have not reviewed this site or any page that quotes them.
  • Quotes are used under fair dealing for criticism and review, each linked to its public recording so you can hear the full context.
  • If a quote here misrepresents what was said, tell us and we will correct it. That correction goes to the front of the queue.

Researchers who want to set out a position in their own words, rather than be quoted, can write for the desk directly.

References

3 sources, all link-checked; oldest check

  1. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. International Committee of Medical Journal Editors, updated 2025.The conflict-of-interest and authorship conventions this desk follows for a lay publication.Verified Sep 14, 2026
  2. PubMed. US National Library of Medicine, National Institutes of Health.The index every citation on this site is checked against before publication.Verified Sep 14, 2026
  3. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Guyatt GH et al. BMJ 2008;336:924.The framework behind the strong / mixed / limited evidence grades used across this site.Verified Sep 14, 2026

Every link above is re-requested on a schedule by an automated checker; the date shown is when it last answered. Publishers that block automated requests are marked as such rather than reported broken. Our editorial standards explain how a source gets cited here in the first place.

Filed by the Rapamycin.store evidence desk. Each source is re-checked when the page is reviewed.

Own a longevity or health brand?

Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.